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Abstract
Neurofilament, light polypeptide (NEFL) was demonstrated to be ectopically expressed in breast cancer tissues and
decreased in lymph node metastases compared to the paired primary breast cancers in our previous study. Moreover, in
several studies, NEFL was regarded as a tumor suppressor gene, and its loss of heterozygosity (LOH) was related to
carcinogenesis and metastasis in several types of cancer. To explore the role of NEFL in the progression of breast cancer and
to evaluate its clinical significance, we detected the NEFL mRNA level in normal breast tissues, primary breast cancer
samples and lymph node metastases, and then analyzed the association between the NEFL expression level and several
clinicopathological parameters and disease-free survival (DFS). NEFL mRNA was found to be expressed in 92.3% of breast
malignancies and down-regulated in lymph node metastases compared to the paired primary tumors. NEFL mRNA level was
lower in primary breast cancers with positive lymph nodes than in cancers with negative lymph nodes. Moreover, a low
expression level of NEFL mRNA indicated a poor five-year DFS for early-stage breast cancer patients. Thus, NEFL mRNA is
ectopically expressed in breast malignancies and could be a potential prognostic factor for early-stage breast cancer
patients.
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Introduction
Neuronal intermediate filaments, or neurofilaments, consist of
three subunits: a light polypeptide (NEFL/NFL), a medium
polypeptide (NEFM/NFM), and a heavy polypeptide (NEFH/
NFH), with molecular weights of 68, 160, and 212 kilodaltons,
respectively [1]. Neurofilaments play a key role in maintaining the
morphology of neurons and in regenerating myelinated axons.
Perturbations in NEFL, the backbone of the neurofilament, have
been suggested to be responsible for motor neuron diseases, such
as Charcot-Marie-Tooth disease, type 2E (CMT2E) [2].
In addition to its influence on the nervous system, NEFL has
been shown to act as a tumor suppressor. The NEFL gene is
located on chromosome 8p21, a region enriched with tumor
suppressor genes, and loss of heterozygosity (LOH) is frequent in
this region [3,4,5]. Accumulating evidence supports that LOH at
8p21 is involved in the carcinogenesis of breast [6,7,8,9,10],
prostate [5,11,12,13,14,15], lung [16,17], colon [4,18], and
urinary bladder cancers [19]. LOH at the NEFL microsatellite is
not only related to carcinogenesis but is also involved in metastasis
of several types of cancers. LOH of the NEFL microsatellite is
more frequent in lymph node and distant organ metastases than in
primary tumor tissues from which the metastasis arose, and it
positively correlates with tumor size, histological grade, lymph
node status, and clinical outcome [8,9,14,20,21]. Furthermore, the
frequency of LOH at the NEFL microsatellite has been reported to
be about 20–40% in breast cancer [6,8,9,10].
NEFL is expressed in neurons with strict histological specificity
in normal tissues. In a previous study, we demonstrated that
ectopic NEFL mRNA expression could be detected in breast
cancers and lymph node metastases; NEFL mRNA expression in
the lymph node metastases was lower than that found in the paired
primary breast cancer tissues [22]. These data indicate that the
ectopic occurrence and change in NEFL mRNA expression level
may play an important role in carcinogenesis and metastasis of
breast cancer. Furthermore, NEFL (BF055311) was included in the
76-gene prognosis signature of breast cancer identified by Wang’s
group [23]. NEFL mRNA expression levels in primary breast
cancer tissues from patients with poor prognoses within five years
were lower than in cancer patients with good outcomes. By far, the
role of NEFL expression in cancer and its power to predict the
prognosis of breast cancer patients are unclear. Therefore, to
explore the role of NEFL in the progression of breast cancer and to
evaluate the clinical significance of NEFL in the predictive power
of NEFL mRNA in determining the prognosis of breast cancer
patients, we used real-time reverse transcription-polymerase chain
reaction (RT-PCR) to measure the expression level of NEFL
mRNA in normal breast tissue samples, primary breast cancer
tissues and lymph node metastases and then analyzed the
association between the NEFL expression level and several
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tumor size, clinical stage, axillary lymph node status, histological
grade, estrogen receptor (ER) status, progesterone receptor (PR)
status, HER2 status, and disease-free survival (DFS).
Results
Expression Level of NEFL mRNA in Breast Tissues
NEFL mRNA could not be detected in any of the 11 normal
breast tissues. Of the breast cancer samples, 91.7% (165/180)
expressed NEFL mRNA as measured by real-time PCR analyses,
and expression ranged from 5.54610
28 to 2.79610
24. NEFL
mRNA was expressed in all of the 14 lymph node metastasis
samples, and expression ranged from 5.52610
28 to 9.46610
26.
The distribution of NEFL mRNA expression in breast tissues did
not accord with a normal distribution. Based on the ROC analysis,
the mRNA value (2.30610
26) capable of distinguishing patients
with relapse or distant metastasis from the patients with DFS in
five years was used to group all of the samples into two groups:
‘‘NEFL-low’’ group (less than 2.30610
26) and ‘‘NEFL-high’’ group
(more than 2.30610
26).
Difference in NEFL mRNA Expression between Malignant
and Normal Breast Tissues
NEFL mRNA was not expressed in all of the normal breast
tissues (11/11), and lower than it in their paired primary breast
cancers (P,0.001). Moreover, NEFL mRNA was expressed in
97% primary cancer tissues and 100% lymph node metastasis
samples, and the difference of NEFL mRNA levels between the
malignant and normal breast tissues was statistically significant
(P,0.001).
Correlation between NEFL mRNA Level and Lymph Node
Metastases
For 14 of the patients with primary breast cancers, the paired
lymph node metastases were available. NEFL mRNA was down-
regulated more than 1.5-fold (from 1.97 to 78.36) in 71.4% (10/
14) of the lymph node samples than in their paired primary
cancer tissues (P=0.011). And the NEFL mRNA expression levels
were lower in the primary cancer specimens with positive lymph
nodes than in cancers with negative lymph nodes. NEFL mRNA
was highly expressed in 56.8% (42/74) of the lymph node-
negative patients, but was highly expressed only in 39.6% (42/
106) of the node-positive cases. This difference in the level of
NEFL mRNA of breast cancer specimens between lymph node-
positive and lymph node-negative cases was statistically signifi-
cant (P=0.023, Table 1).
Correlation between NEFL mRNA Level and
Clinicopathological Factors
No significant differences in the NEFL mRNA level were found
for any of the different clinicopathological factors, including
menopausal status, tumor size, clinical stage, nuclear grade, ER
status, PR status, and HER2 status (P.0.05, Table 1).
Correlation between NEFL mRNA Level and Disease-free
Survival
In the 174 cases with follow-up data for more than three years,
the 3-year DFS rate was 77.2% (71/92) in patients with low-
expressed NEFL and 87.8% (72/82) in the patients with high-
expressed NEFL. The 5-year DSF rates were 54.3% (38/70) and
80.4% (45/56) in patients with low-expressed NEFL and patients
with high-expressed NEFL, respectively. Kaplan and Meier
survival analysis suggests that the DFS time of patients with low-
expressed NEFL was shorter than the DFS of patients with high-
expressed NEFL (P=0.004, Figure 1A). The sensitivity and
specificity of NEFL mRNA expression levle to predict the clinical
outcome of breast cancer patients were 74.4% and 53.3%,
respectively (Table 2). Next, tumor size, clinical stage, histolog-
ical grade, lymph node status, ER status, PR status, HER2
status, and NEFL level were analyzed in a Cox’s multivariate
analysis. As a result, tumor size greater than 5 cm [OR=2.26
(95% CI 0.92–4.99), P=0.079], high nuclear grade [OR=2.70
(95% CI 1.28–5.71), P=0.009], negative PR [OR=2.32 (95%
CI 1.05–5.13), P=0.038], and low-expressed NEFL [OR=2.69
(95% CI 1.24–5.88), P=0.013] were independent factors in
predicting the relapse or distant metastasis of breast cancer
patients (Table 3).
When the survival status of the patients with different NEFL
expression levels and different stages of progression was analyzed,
NEFL mRNA expression level was found to be a prognostic factor
to predict DFS of early-stage breast cancer patients, including
patients with clinical stage I/II disease (P=0.0004, Figure 1B),
patients with negative lymph nodes (P=0.008, Figure 1C), and
patients with histological grade I/II tumors (P=0.006, Figure 1D).
However, NEFL mRNA had a low predictive power to determine
the DFS of late-stage breast cancer patients (P.0.05, Figure 1).
Both the sensitivity and specificity to predict relapse or distant
metastasis were higher in clinical stage I/II patients (85.7% and
54.1%, respectively), in node-negative patients (88.9% and 63.1%,
respectively), or in histological grade I/II patients (76.9% and
Table 1. Correlation between NEFL mRNA Level and
Clinicopathological Factors.




Lymph node status Negative 74 32 42 0.023
Positive 106 64 42
Menopausal status Pre-/peri- 96 54 42 0.364
Post- 79 39 40
missing 5 3 2
Tumor size (cm) ,=2 76 40 36 0.872
.2 104 56 48
Clinical stage I+II 150 80 70 1.000
III 30 16 14
Histological grade I+II 126 63 63 0.475
III 26 15 11
missing 28 18 10
ER status Positive 102 48 54 0.156
Negative 67 39 28
missing 11 9 2
PR status Positive 79 40 39 0.946
Negative 86 44 42
missing 15 12 3
HER2 status Positive 112 58 54 0.806
Negative 52 28 24
missing 16 10 6
doi:10.1371/journal.pone.0031146.t001
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metastasis in overall breast cancer patients (74.4% and 53.3%,
respectively; Table 2). In patients with clinical stage I/II, negative
lymph nodes, and histological grade I/II, the hazard of relapse or
distant metastasis of patients with low-expressed NEFL was 5.13-,
12.20-, and 2.78-fold higher, respectively, than in patients with
high-expressed NEFL (Table 3).
Discussion
In the present study, NEFL mRNA was found to be ectopically
expressed in breast malignancies. NEFL mRNA expression level
was down-regulated in lymph node metastases compared to their
paired primary tumors and was lower in the primary breast tumors
of patients with positive lymph nodes than in patients with
negative lymph nodes. Moreover, expression levels of NEFL
mRNA indicated poor DFS in early-stage breast cancer patients.
Although NEFL mRNA is expressed only in neurons with strict
histology specificity in normal tissues, our study shows that NEFL
mRNA is ectopically expressed in breast malignancies. These data
are also supported by the findings of Wang’s group [23]. In several
previous studies [3,4,5], NEFL has been regarded as a tumor
suppressor gene, and its LOH has been related to the
carcinogenesis of several types of cancer. Wiedau-Pazos et al.
[24] suggested a link between Cu2+/Zn2+ superoxide dismutase
(SOD1) mutations, which could increase the peroxidase activity of
SOD1 and result in the increased production of hydroxyl radicals
from hydrogen peroxide, and the formation of neurofilament
accumulations. Julien et al. [25] speculated that neurofilaments
might have a protective role against the toxic effects induced by
Figure 1. DFS is decreased in patients with low-expressed NEFL. Kaplan-Meier survival curves based on NEFL mRNA levels (A), NEFL mRNA
levels combined with different clinical stages (B), lymph node status (C), and histological grades (D).
doi:10.1371/journal.pone.0031146.g001
Table 2. Sensitivity and Specificity of NEFL mRNA Levels and Other Clinicopathological Variables to Predict the Relapse or Distant
Metastasis in Five Years of Breast Cancer Patients.
Variables Overall Clinical Stage I/II Negative lymph node Histological Grade I/II
Sensitivity (%) Specificity (%) Sensitivity (%) Specificity (%) Sensitivity (%) Specificity (%) Sensitivity (%) Specificity (%)
NEFL 74.4 (32/43) 53.3 (73/137) 85.7 (24/28) 54.1 (66/122) 88.9 (8/9) 63.1 (41/65) 76.9 (20/26) 57.0 (57/100)
Tumor size 74.4 (32/43) 47.4 (65/137) 60.7 (17/28) 50.0 (61/122) 55.6 (5/9) 49.2 (32/65) 73.1 (19/26) 46.0 (46/100)
Lymph node
status
79.1 (34/43) 47.4 (65/137) 78.6 (22/28) 51.6 (63/122) NA NA 73.1 (19/26) 45.0 (45/100)
Clinical stage 34.9 (15/43) 89.1 (122/137) NA NA 50.0 (3/6) 96.9 (63/65) 38.5 (10/26) 88.0 (88/100)
Grade 25.6 (11/43) 87.0 (100/115) 33.3 (8/24) 87.1 (88/101) 11.1 (1/9) 86.5 (45/52) NA NA
ER 48.8 (20/41) 63.3 (81/128) 34.6 (9/26) 63.0 (73/114) 33.3 (3/9) 62.3 (38/61) 46.2 (12/26) 68.0 (66/97)
PR 69.2 (27/39) 53.2 (67/126) 60.0 (15/25) 57.1 (64/112) 50.0 (4/8) 50.8 (31/61) 77.3 (17/22) 60.0 (57/95)
HER2 43.9 (18/41) 73.2 (90/123) 37.0 (10/27) 75.2 (82/109) 55.6 (5/9) 70.4 (38/54) 48.0 (12/25) 72.3 (68/94)
doi:10.1371/journal.pone.0031146.t002
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hypothesize that the change in NEFL mRNA expression level is
involved in the process of adaptive cytoprotection of the variant
tissue cells. When malignant transformation happens under
cumulative physical and chemical carcinogenic factors, tissue cells
change their expression profile to adapt to the new microenvi-
ronment and to retain the function of normal tissue cells as much
as possible [26]. NEFL may be one of the genes related to
cytoprotection. If the expression level of NEFL could not be
increased correspondingly in breast cancer carcinogenesis and
progression due to LOH or signal pathway in disorder, cancer cells
would display a highly malignant phenotype and lead to metastasis
of cancer cells and poor prognosis of patients.
The cause of the decrease in the NEFL mRNA level in lymph
node metastases and in primary cancers with poor clinical outcomes
remains unclear. LOH of NEFL may be one of the possible reasons
why NEFL mRNA levels are lower in primary tumors with high
metastatic potential compared to tumors with low metastatic
potential. LOH of NEFL has been reported to be a late event in
the progression of colon, prostate, and bladder cancer [27];
however, Yaremko and his colleagues [10] proved that LOH of
NEFL did not correlate with tumor size, histologic grade, receptor
status, and DNA ploidy, suggesting LOH of NEFL is an early event
in breast cancers. This also explained why NEFL mRNA levels were
not decreased in tumors with clinical stage III or with larger tumors
(.2 cm) comparing to earlier stages or smaller tumors (,=2 cm).
Another possible reason may be due to a single nucleotide
polymorphism (SNP) in the promoter of the NEFL gene [28,29].
Buckland et al. showed that a single A/G sequence variant at 2172
in the promoter of the NEFL gene could influence the transcription
of NEFL mRNA, with the G allele having 1.7-fold greater activity
than the A allele [28,29]. Another unknown variant of the NEFL
gene or a changed signaling pathway may also be involved in the
dynamic change in the NEFL mRNA expression level.
Kaplan and Meier survival analysis suggests that low NEFL
mRNA levels indicate a short DFS for breast cancer patients. The
hazard of relapse or distant metastasis within five years in NEFL-
low patients was 2.32-fold higher than in NEFL-high patients.
Furthermore, when the survival status of patients with different
stages of disease progression was analyzed, NEFL mRNA was
found to be a prognostic factor to predict DFS of early-stage breast
cancer patients. Although both of the sensitivity and specificity of
NEFL mRNA in predicting the relapse or distant metastasis within
five years were not the highest compared with other clinicopath-
ological variables for overall breast cancer patients, the sensitivity
of NEFL mRNA was higher than other factors for patients in
clinical stage I/II and negative lymph node metastasis stratifica-
tions. In addition, the sensitivity of was closed to the highest (PR)
in histological Grade I/II stratification. Based on the systemic
therapy guidelines currently in effect, more than 50% of breast
cancer patients with early-stage disease (clinical stage I/II,
negative lymph node, and histological grade I/II) may not benefit
from post-mastectomy chemotherapy or radiotherapy treatment
and may potentially suffer from their side effects. NEFL mRNA
level, as a potential prognostic factor for early-stage breast cancer,
could help oncologists choose individual therapeutic strategies. In
this study, NEFL mRNA was found had a low predictive power to
predict the DFS of late-stage breast cancer patients. The reason for
the failure of NEFL mRNA to predict the DFS of late-stage
patients may be due to the fact that cancer cells have highly
malignant phenotypes and high metastatic potentials when tumors
advance to a late-stage, and the change in expression of
cytoprotection-related genes cannot arrest the appearance of
metastases. In addition, the small number of late-stage cases used
in this study might be another reason that no statistic difference
was found between the DFS of late-stage patients with different
NEFL mRNA status.
In conclusion, NEFL mRNA was expressed in breast malignan-
cies, and a decreased expression of NEFL indicated a poor long-
term survival in early-stage breast cancer patients. Thus, NEFL
mRNA expression level could be a potential prognosis prediction
marker in breast cancer patients.
Materials and Methods
Patients and Follow-up
All of the 180 breast cancer patients who were used in the
present study underwent complete dissection of the breast and
axillary lymph nodes without preoperative chemotherapy at
Tianjin Medical University Cancer Institute and Hospital
(TMUCIH), China, between January 2001 and November 2004.
After surgery, 165 breast cancer cases were treated with
chemotherapy; 102 cases with positive ER status were treated
with tamoxifen as a hormone therapy; and 97 cases were treated
by radiotherapy. All of the breast cancer patients were followed up
until May of 2009. DFS was defined as the time interval from
surgery to first local relapse/distant organ metastases (patients with
relapse or distant metastasis) or to the last follow-up visit (patients
with disease-free survival). Of the 180 breast cancer cases, 174
cases were followed for more than three years (31 cases with
relapse or distant metastasis and 143 cases with DFS), and 126
cases were followed for more than five years (43 cases with relapse
or distant metastasis and 83 cases with DFS). The median follow-
up time was 65 months.
Specimen Characteristics
All the specimens used in the present study, 11 normal breast
tissue samples, 180 primary tumors and 14 lymph node metastasis
Table 3. Hazard Ratios of Breast Cancer Patients Developing into Relapse or Distant Metastasis Based on Different NEFL mRNA
Levels and the Status of Other Clinicopathological Prognostic Factors.
Variables Overall Clinical Stage I–II Negative lymph node Histological Grade I–II
OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P
NEFL-low 2.69 (1.23–5.88) 0.013 5.13 (1.72–15.15) 0.003 12.20 (1.43–100.00) 0.022 2.78 (1.07–7.19) 0.036
Tumor size .2c m 2.14 (0.92–4.99) 0.079 1.84 (0.74–4.59) 0.193 1.11 (0.23–5.38) 0.893 1.96 (0.71–5.45) 0.196
Grade III 2.70 (1.28–5.71) 0.009 3.16 (1.29–7.74) 0.012 1.28 (0.14–11.77) 0.826 NA NA
PR-negative 2.32 (1.05–5.13) 0.038 2.07 (0.84–5.10) 0.113 1.16 (0.25–5.32) 0.845 4.12 (1.51–11.24) 0.006
doi:10.1371/journal.pone.0031146.t003
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samples were snap-frozen in liquid nitrogen and stored at 280uC.
All samples were examined by hematoxylin-eosin (H&E) staining,
and only the normal tissue samples with 50% or more epithelial
cells and tumor samples that consisted of 75% or more cancer cells
were selected for real-time RT-PCR. ER expression and PR
expression were determined as positive when more than 1% of the
nuclei were stained by immunohistochemical staining. HER2 was
defined as positive when more than 10% of the membrane was
stained by an immunohistochemical assay. The study protocol was
approved by the Institutional Review Board and the Research
Ethics Committee of TMUCIH and written consent was obtained
from all participants.
Real-time RT-PCR Assay
RNA was extracted with TRIZOL reagent (Invitrogen, Gai-
thersburg, MD, USA) according to the manufacturer’s instructions.
Then, 5 mg of total RNA was used to perform reverse transcription
(RT)for first-strand cDNA synthesis. RNAwasdenatured for 5 min
at 65uC and snap cooled on ice in the presence of 0.5 mg Oligo(dT)
and 10 mmol dNTP mix. The sample was then incubated at 4uC
for 50 min with First-Strand Buffer, 0.2 mmol DTT, 40 units of
RNaseOUT ribonuclease inhibitor and 200 units of SuperScript II
in a total volume of 20 mL. The reactions were stopped by
incubation at 70uC for 15 min. All of the reagents used for RT were
from Invitrogen.
Real-time RT-PCR was performed using the Platinum
Quantitative PCR SuperMix-UDG System (Invitrogen). We
quantified the transcripts of the GAPDH housekeeping gene as a
control as previously described [30]. Primers and TaqMan probes
for NEFL were as follows: 59-CCTGGAAATCGAAGCAT-39,5 9-
ATTTCACTCTTTGTGGTCCTC-39, and 59-(FAM) ATTT-
GTTGATCGTGTCCTGCATAGC (TAMRA)-39. Assays were
performed with the ABI 7500 TaqMan system (Applied
Biosystems, Foster City, CA, USA). PCR was carried out after
incubation at 50uC for 2 min and pre-denaturing at 95uC for
3 min, followed by 40 cycles at 95uC for 30 sec and 62uC for
1 min. The relative quantification was given by the CT values,
determined by triplicate reactions for all of the samples for both
NEFL and GAPDH. The triplicate CT values of NEFL were
averaged, and the CT value of GAPDH was subtracted to obtain




RNA was extracted from cancer tissues taken from 10 breast
cancer patients and pooled equally as the quality control RNA.
Quality control RNA and Diethylpyrocarbonate (DEPC)-treated
water, served as the positive and negative control samples,
respectively,were used to perform RT and real-time PCR with
each of the different batches of assays. If the expression levels of
NEFL or GAPDH in the negative control samples were detectable
or the expression level in the positive control RNA was beyond the
95% confidence interval of the mean NEFL or GAPDH expression
level of the quality control RNA, the expression levels in that batch
of samples were assayed again.
Statistical Analysis
The distribution of NEFL mRNA expression in breast tissues did
not accord with normal distribution, therefore, the relationship
between NEFL and various clinicopathological variables was
analyzed by the chi-square test or the Fisher’s exact test, as
appropriate. The differences of NEFL mRNA levels between
normal breast tissues and paired primary breast cancer samples
and between primary cancer samples and paired lymph node
metastases were calculated using Wilcoxon signed-rank test. The
cut-off value for distinguishing patients with a poor prognosis from
patients with a good prognosis was determined by calculating the
receiver operating characteristic (ROC) curve and area under
curve (AUC). Survival analysis was carried out according to the
methods of Kaplan and Meier and log-rank test. Multivariate
survival analysis was performed by a backward stepwise Cox
proportional hazards regression model. All calculations were
performed with the SPSS for Windows statistical software package
(SPSS Inc, Chicago, IL, USA).
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